Business context and reporting period
Rocket Pharmaceuticals, Inc. filed this 10-K for the fiscal year ended December 31, 2017. The audited statements in the filing are for Inotek Pharmaceuticals Corporation, the legal predecessor—not the post-merger Rocket business. On January 4, 2018, Inotek merged with privately held Rocket Pharmaceuticals, Ltd.; Private Rocket is treated as the accounting acquirer. Historical results therefore should not be read as consolidated 2017 results for the combined company.
Before the merger, Inotek was developing trabodenoson for ocular disease and discontinued the program in 2017 after clinical trials missed primary endpoints. The combined company focuses on gene therapies for rare pediatric diseases. Its pipeline included two Fanconi anemia programs in clinical testing and preclinical programs for LAD-I, PKD, IMO, an undisclosed AAV indication, and CRISPR/Cas9 gene editing.
Financial performance and position
Unless otherwise noted, financial amounts below are Inotek’s historical results, in millions of dollars. The filing reports no product revenue for Inotek or Private Rocket; margins are therefore not meaningful.
| Metric | 2017 | 2016 |
|---|---|---|
| Research and development expense | $14.2 | $32.0 |
| General and administrative expense | $12.5 | $9.9 |
| Operating loss | $26.7 | $41.9 |
| Net loss | $29.5 | $42.9 |
| Net loss per share | $4.36 | $6.41 |
| Cash used in operating activities | $26.1 | $37.3 |
- Inotek ended 2017 with $78.7 million of cash and cash equivalents and $21.3 million of short-term investments, totaling $100.0 million; current liabilities were $4.1 million.
- Inotek reported $49.5 million carrying value of 2021 convertible notes at year-end, against $52.0 million principal. The unsecured notes bear 5.75% interest and mature August 2021; stated future principal and interest obligations totaled $64.0 million.
- Inotek’s total assets were $101.8 million, total liabilities $54.0 million, and stockholders’ equity $47.8 million at December 31, 2017. Accumulated deficit was $268.4 million.
- Investing activities provided $75.0 million in 2017, primarily from maturities of short-term investments; this was portfolio turnover, not operating cash generation.
- Separately, Private Rocket reported 2017 R&D expense of $14.9 million versus $6.0 million in 2016, net loss of $19.6 million versus $7.6 million, accumulated deficit of $31.3 million, and cash of $18.1 million at year-end.
Changes, outlook, and material items
- Inotek’s net loss narrowed by $13.4 million year over year, primarily because R&D expense fell $17.8 million as trabodenoson clinical and preclinical work wound down. G&A rose $2.6 million, including $2.3 million of merger-related costs. Interest expense increased $2.2 million, reflecting a full year of interest on the 2021 notes.
- Inotek’s operating cash use declined by $11.2 million versus 2016. Its cash balance rose partly because short-term investments matured; financing cash flow was only $0.02 million in 2017.
- After the merger, the company completed a January 2018 public offering and received approximately $78.8 million net proceeds. Management stated that December 2017 cash plus offering proceeds were expected to fund operating expenses and capital requirements through at least March 2019. The company expects continuing losses and says additional funding will be needed.
- Management’s stated development plans included announcing Fanconi anemia data in 2018, advancing an FA program toward a pivotal trial in 2019, and pursuing an IND for the preclinical AAV program within 12 months. These are expectations, not guaranteed milestones.
- At March 1, 2018, the company reported three RP-L101 and five RP-L102 patients treated; it reported no serious, unexpected side effects to date and described early observations for RP-L102 patients as preliminary. Results remain early and do not establish safety or efficacy.
- Material risks include clinical and regulatory uncertainty, rare-disease enrollment challenges, reliance on third-party manufacturers and research partners, limited and largely in-licensed intellectual property, potential need for further financing and dilution, and the possibility that gene therapy risks or manufacturing issues delay development.
- A putative securities class action against Inotek and two individuals concerning statements about trabodenoson trials remained pending; defendants were seeking dismissal and the company said it was vigorously defending the case. Inotek also recorded a $0.4 million impairment of laboratory equipment after discontinuing trabodenoson.
- The filing reports effective disclosure controls and internal control over financial reporting as of December 31, 2017; the auditor did not provide an internal-control attestation.
Most important facts for investors to verify
- Confirm the accounting distinction: 2017 audited statements are Inotek’s, while Private Rocket’s disclosed historical figures are separate; they are not combined-company 2017 results.
- Check the merger accounting and pro forma share count, including the January 2018 1-for-4 reverse split, exchange ratio, and subsequent 6.325 million-share offering.
- Track actual cash burn and runway against management’s estimate through March 2019, as well as the timing and terms of any further financing.
- Assess clinical-trial updates, patient follow-up, safety, efficacy, and whether anticipated regulatory filings and trial milestones were achieved.
- Review the convertible notes’ terms and repayment or conversion implications, and monitor the pending securities litigation and any resulting costs or disclosures.